Literature DB >> 32701441

Predictors of prostate bed recurrence on magnetic resonance imaging in patients with rising prostate-specific antigen after radical prostatectomy.

Nicola J Nasser1, Victoria Chernyak2, Viswanathan Shankar3, Madhur Garg1, William Bodner1, Shalom Kalnicki1, Jonathan Klein1.   

Abstract

INTRODUCTION: Radical prostatectomy (RP) is a standard treatment modality for localized prostate cancer. Biochemical failure after RP is usually evaluated with whole-body imaging to exclude distant metastatic disease, and pelvic magnetic resonance imaging (MRI) to detect local recurrence in the prostatectomy bed. The goal of this study is to correlate disease characteristics and demographic data in patients with rising prostate-specific antigen (PSA) after RP to determine association with MRI-detected cancer recurrence.
METHODS: Sixty-four patients who underwent pelvic MRI for rising PSA after RP and had complete clinical and pathological data available were included. Using Chi-squared testing, we analyzed PSA levels, pathological disease characteristics (prostate cancer risk group, Gleason score, extracapsular extension, positive surgical margin, seminal vesicle involvement, perineural invasion, lymphovascular invasion, and PSA level before MRI), time from surgery to biochemical failure, and patient demographic characteristics as potential predictors of MRI-detected local recurrence.
RESULTS: Definite MRI-detected local recurrence was observed in 17/64 patients (27%). Eleven (17%) patients had a suspicious lesion with the differential of scarring, retained seminal vesicle, or recurrent cancer. Thirty-six (56%) patients had no evidence of tumor in the prostate bed or pelvis on MRI. Patient race was associated with likelihood of detecting a prostate nodule on MRI (p=0.04), with African American patients having 82% lower odds of MRI-detected tumor recurrence compared with white patients (p=0.045). No other tumor or patient characteristic was significantly associated with MRI-detected recurrence.
CONCLUSIONS: African American patients with biochemical failure after RP are less likely to have MRI-detectable recurrence in the prostate bed compared with white patients.

Entities:  

Year:  2021        PMID: 32701441      PMCID: PMC7769522          DOI: 10.5489/cuaj.6463

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN: 1911-6470            Impact factor:   1.862


  37 in total

1.  Sector analysis of dosimetry of prostate cancer patients treated with low-dose-rate brachytherapy.

Authors:  Nicola J Nasser; Yinkun Wang; Jette Borg; Elantholi P Saibishkumar
Journal:  Brachytherapy       Date:  2014-02-20       Impact factor: 2.362

2.  Prostate cancer survival in the United States by race and stage (2001-2009): Findings from the CONCORD-2 study.

Authors:  C Brooke Steele; Jun Li; Bin Huang; Hannah K Weir
Journal:  Cancer       Date:  2017-12-15       Impact factor: 6.860

3.  Impact of 11C-choline PET/CT on clinical decision making in recurrent prostate cancer: results from a retrospective two-centre trial.

Authors:  Francesco Ceci; Ken Herrmann; Paolo Castellucci; Tiziano Graziani; Christina Bluemel; Riccardo Schiavina; Christian Vollmer; Sabine Droll; Eugenio Brunocilla; Renzo Mazzarotto; Andreas K Buck; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-08-15       Impact factor: 9.236

4.  Inter-institutional analysis demonstrates the importance of lower than previously anticipated dose regions to prevent late rectal bleeding following prostate radiotherapy.

Authors:  Maria Thor; Andrew Jackson; Michael J Zelefsky; Gunnar Steineck; Asa Karlsdòttir; Morten Høyer; Mitchell Liu; Nicola J Nasser; Stine E Petersen; Vitali Moiseenko; Joseph O Deasy
Journal:  Radiother Oncol       Date:  2018-03-09       Impact factor: 6.280

5.  Evaluation of the prostate bed for local recurrence after radical prostatectomy using endorectal magnetic resonance imaging.

Authors:  Stanley L Liauw; Sean P Pitroda; Scott E Eggener; Walter M Stadler; Charles A Pelizzari; Michael W Vannier; Aytek Oto
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-06-18       Impact factor: 7.038

6.  Perineural invasion as a predictor of biochemical outcome following radical prostatectomy for select men with clinically localized prostate cancer.

Authors:  A V D'Amico; Y Wu; M H Chen; M Nash; A A Renshaw; J P Richie
Journal:  J Urol       Date:  2001-01       Impact factor: 7.450

7.  ACR Appropriateness Criteria® Post-treatment Follow-up Prostate Cancer.

Authors:  Adam T Froemming; Sadhna Verma; Steven C Eberhardt; Aytekin Oto; Lauren F Alexander; Brian C Allen; Fergus V Coakley; Brian J Davis; Pat F Fulgham; Keyanoosh Hosseinzadeh; Christopher Porter; V Anik Sahni; David M Schuster; Timothy N Showalter; Aradhana M Venkatesan; Carolyn L Wang; Erick M Remer
Journal:  J Am Coll Radiol       Date:  2018-05       Impact factor: 5.532

8.  Detection of recurrent prostate cancer after radical prostatectomy: comparison of 11C-choline PET/CT with pelvic multiparametric MR imaging with endorectal coil.

Authors:  Kazuhiro Kitajima; Robert C Murphy; Mark A Nathan; Adam T Froemming; Clinton E Hagen; Naoki Takahashi; Akira Kawashima
Journal:  J Nucl Med       Date:  2014-01-16       Impact factor: 10.057

9.  Cancer survival in five continents: a worldwide population-based study (CONCORD).

Authors:  Michel P Coleman; Manuela Quaresma; Franco Berrino; Jean-Michel Lutz; Roberta De Angelis; Riccardo Capocaccia; Paolo Baili; Bernard Rachet; Gemma Gatta; Timo Hakulinen; Andrea Micheli; Milena Sant; Hannah K Weir; J Mark Elwood; Hideaki Tsukuma; Sergio Koifman; Gulnar Azevedo E Silva; Silvia Francisci; Mariano Santaquilani; Arduino Verdecchia; Hans H Storm; John L Young
Journal:  Lancet Oncol       Date:  2008-07-17       Impact factor: 41.316

10.  Pelvic MRI findings in relapsed prostate cancer after radical prostatectomy.

Authors:  D Hernandez; D Salas; D Giménez; P Buitrago; S Esquena; J Palou; P de la Torre; J Pernas; I Gich; G Gómez de Segura; J Craven-Bartle; G Sancho
Journal:  Radiat Oncol       Date:  2015-12-24       Impact factor: 3.481

View more
  1 in total

1.  Pathological predictors of 18 F-DCFPyL prostate-specific membrane antigen-positive recurrence after radical prostatectomy.

Authors:  Elisa Perry; Arpit Talwar; Kim Taubman; Michael Ng; Lih-Ming Wong; Tom R Sutherland
Journal:  BJU Int       Date:  2022-06       Impact factor: 5.969

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.